WTA
ANIK icon

Washington Trust Advisors’s Anika Therapeutics ANIK Stock Holding History

Washington Trust Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-153
Closed -$3K – 901
2022
Q2 		$3K Hold
153
– – ﹤0.01% 810
2022
Q1 		$4K Hold
153
– – ﹤0.01% 838
2021
Q4 		$5K Buy
+153
New +$6.12K ﹤0.01% 838

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Washington Trust Advisors's ANIK Position: Q3 2022 in Review

Washington Trust Advisors sold out of Anika Therapeutics (ANIK) in Q3 2022, closing a stake of 153 shares — an estimated $3K sold.

Washington Trust Advisors first reported a position in ANIK in Q4 2021 and held it in 3 quarters. The position peaked at $5K in Q4 2021. 121 funds tracked by Wall St. Rank hold ANIK as of Q3 2022.

  • Washington Trust Advisors reported no remaining Anika Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Washington Trust Advisors sold 153 Anika Therapeutics shares in Q3 2022, an estimated $3K.
  • Washington Trust Advisors first reported a position in Anika Therapeutics in Q4 2021 and held it in 3 quarters.
  • Washington Trust Advisors's Anika Therapeutics position peaked at $5K in Q4 2021.
  • 121 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2022.

Based on Washington Trust Advisors's 13F filing for Q3 2022, filed 14 Oct 2022.